Biotech IV Monitor

ARGX — argenx SE

$64.0B market cap · 7 upcoming readouts tracked

Clinical trial readout dates for argenx SE, compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is March 2027.

Next readoutMarch 2027in ~4 months
Upcoming readouts74 Phase 3
Market cap$64.0B

Recently completed

The registry reports these trials have finished collecting primary data. Results often follow within months, and the company may already have reported.

Phase 2/3 EFG PH20 SC
Active Idiopathic Inflammatory Myopathy; Myositis · NCT05523167
July 2026
Primary data collected

Upcoming readouts

Phase 2/3 Efgartigimod IV
Generalized Myasthenia Gravis · NCT04833894
March 2027
Ongoing
Phase 2 Efgartigimod PH20 SC
Systemic Sclerosis (SSc) · NCT06655155
March 2027
Ongoing
Phase 2 Efgartigimod PH20 SC
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) · NCT04280718
April 2027
Ongoing
Phase 3 Efgartigimod PH20 SC
Primary Sjogrens Disease · NCT06684847
July 2027
Ongoing
Phase 2/3 Efgartigimod PH20 SC
Generalized Myasthenia Gravis · NCT06392386
September 2027
Recruiting
Phase 3 empasiprubart
Chronic Inflammatory Demyelinating Polyneuropathy; CIDP · NCT06920004
September 2027
Recruiting
Phase 2 Empasiprubart IV
AChR-Ab Seropositive Generalized Myasthenia Gravis; Myasthenia Gravis (MG) · NCT07673627
October 2027
Recruiting

Target dates already passed

These dates have elapsed; the company may have reported, or guidance may have shifted.

Phase 2 Empasiprubart IV
Dermatomyositis; Myositis · NCT06284954
November 2026
Ongoing

Companies working on similar indications

Discussion

No messages yet. If you follow ARGX, you can start the conversation.
Track ARGX in real time
See live implied volatility for ARGX and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on ARGX
Contact — questions or corrections about ARGX: dukeupt@gmail.com